Study directory

Mental health studies with practical context.

Compare studies and check their requirements with the research team.

Back to overview

10612studies shown

Showing 109-120 of 10,612

Drug study icon

RecruitingNCT06951711

KarXT for manic episodes in bipolarity type I

The registry lists this study as recruiting. Study locations are listed in the United States, in China, in Croatia, ...

In United States

BipolarityDrugFrom 18 Years to 65 Years

Countries: United States, China, Croatia, ...
Sponsor: Bristol-Myers Squibb
Condition: Bipolarity

Drug study icon

RecruitingNCT07288567

KarXT for schizophrenia

The registry lists this study as recruiting. Study locations are listed in the United States, in Colombia, in Japan, ...

In United States

SchizophreniaDrugFrom 13 Years to 17 Years

Countries: United States, Colombia, Japan, ...
Sponsor: Bristol-Myers Squibb
Condition: Schizophrenia

Drug study icon

RecruitingNCT07065240

SPT-300 (GlyphAllo) for depression

The registry lists this study as recruiting. Study locations are listed in the United States, in Bulgaria, in Czechia, ...

In United States

DepressionDrugFrom 18 Years to 65 Years

Countries: United States, Bulgaria, Czechia, ...
Sponsor: Seaport Therapeutics
Condition: Depression

Drug study icon

RecruitingNCT06223880

Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms

The registry lists this study as recruiting. Study locations are listed in the United States.

In United States

DepressionDrugFrom 18 Years to 65 Years

Countries: United States
Sponsor: Axsome Therapeutics, Inc.
Condition: Depression

Drug study icon

RecruitingNCT07424404

KarXT and KarX-EC for schizophrenia

The registry lists this study as recruiting. Study locations are listed in the United States, in Australia, in France, ...

In United States

SchizophreniaDrugFrom 5 Years to 17 Years

Countries: United States, Australia, France, ...
Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Condition: Schizophrenia

Drug study icon

RecruitingNCT07196501

Maintenance Effect of NBI-1065845 for depression

The registry lists this study as recruiting. Study locations are listed in the United States, in Australia, in Canada, ...

In United States

DepressionDrugOver 18 Years

Countries: United States, Australia, Canada, ...
Sponsor: Neurocrine Biosciences
Condition: Depression

Drug study icon

RecruitingNCT07061288

Safety, Tolerability, and PK of an Injectable Form of KarXT

The registry lists this study as recruiting. Study locations are listed in the United States.

In United States

SchizophreniaDrugFrom 18 Years to 55 Years

Countries: United States
Sponsor: Bristol-Myers Squibb
Condition: Schizophrenia

Drug study icon

RecruitingNCT07621237

TNX-102 SL Monotherapy Versus Placebo in people with Major Depressive Disorder (MDD)

The registry lists this study as recruiting. Study locations are listed in the United States.

In United States

DepressionDrugOver 18 Years

Countries: United States
Sponsor: Tonix Pharmaceuticals, Inc.
Condition: Depression

Drug study icon

RecruitingNCT07540338

A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolarity type I

The registry lists this study as recruiting. Study locations are listed in the United States.

In United States

BipolarityDrugFrom 18 Years to 65 Years

Countries: United States
Sponsor: Alzamend Neuro, Inc.
Condition: Bipolarity

Device study icon

RecruitingNCT07405398

A Study to Train a Machine Learning Algorithm for an Evaluation of the Use of Biometric Data Captured at the Wrist for the Identification of Acute Opioid Use Events and the Quantification of Opioid Withdrawal in Opioid Dependent Individuals

The registry lists this study as recruiting. Study locations are listed in the United States.

In United States

AddictionDeviceOver 22 Years

Countries: United States
Sponsor: OpiAID
Condition: Addiction

Behavioral study icon

RecruitingNCT03803332

Trial Comparing Interpersonal Therapy to Exposure Therapy for PTSD

The registry lists this study as recruiting. Study locations are listed in the United States.

In United States

PTSDBehavioralFrom 18 Years to 85 Years

Countries: United States
Sponsor: Weill Medical College of Cornell University
Condition: PTSD

Drug study icon

RecruitingNCT06248229

A study of Dyanavel XR in Treating Co-occurring Fatigue Symptoms in Adults With Attention Deficit Hyperactivity Disorder (ADHD).

This summary needs review. Please check the official study record and contact the research team for details.

In United States

ADHDDrugFrom 18 Years to 65 Years

Countries: United States
Sponsor: Rochester Center for Behavioral Medicine
Condition: ADHD

Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.